Colaboraciones

Max Vento. Director Neonatal Research Unit, Division of Neonatology, University Hospital Materno-Infantil La Fe, Valencia, Spain. “Antioxidant effects of cannabidiol”. Since 2006.

Roger G. Pertwee, Institute of Medical Sciences at the University of Aberdeen, Scotland, UK. “Neuroprotective effect of cannabidiol in hypoxic-ischemic damage in immature brain”. Since 2007.

Francisco J. Alvarez. Research Unit on Experimental Perinatal Physiopathology, Gurutzetako Ospitalea, Bizkaia, Spain. “Pharmacological profile of cannabidiol for the treatment of newborn hypoxic-ischemic brain damage”. Since 2007.

Cecilia J. Hillard. Director of the Neuroscience Research Center. Medical College of Wisconsin, USA. “Involvement of CB2 receptors in cannabidiol neuroprotection in asphyxiated piglets”. Since 2011.

Raphael Mechoulam. School of Pharmacy. Hebrew University of Jerusalem, Israel. “Cannabinoid-based therapy for neonatal stroke”. Since 2011.

Rafael Franco, Senior Researcher of the group “neurofarmacología celular y molecular: neuroprotección”, Centro de Investigación Médica Aplicada de la Universidad de Navarra. Since 2011

Ola D. Saugstad, Professor of Pediatrics at the University of Oslo. Director of Department of Pediatric Research Consultant in Neonatology Rikshospitalet, University of Oslo, Norway. Since 2012.

Rafael Franco, Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED). Instituto de Salud Carlos III, Madrid;  Laboratorio de Neurobiología Molecular, Departamento de Bioquímica Y Biomedicina Molecular, Universitat de Barcelona, Barcelona.

  Emerald Health Biotechnology España  (desde 2018) Research agreement”Neuroprotective effects of VCE-005.3- in neonatal hypoxic-ischemic brain damage”.

Emerald Health Pharmaceuticals España  (desde 2020) Research agreement  “VCE-004.8 for stroke management in newborns”.​